ALDX

Aldeyra Therapeutics Inc

Aldeyra Therapeutics (NASDAQ:ALDX) Stock Crosses Above 50-Day Moving Average - Here's Why...

Aldeyra Therapeutics (NASDAQ:ALDX) Share Price Crosses Above 50 Day Moving Average - What's Next...

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX - Get Free Report) saw some unusual options trading activity on Tuesday. Investors bought 12,807 call options on the stock. This is an increase of 1,592...

The FDA delayed its decision on the dry eye drug Reproxalap to March 2026 without raising new issues, while review and labeling discussions continued.

683 Capital Management LLC grew its position in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX - Free Report) by 126.9% during the second quarter, according to the company in its most recent 13F filing with...

Kennedy Capital Management LLC lessened its position in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX - Free Report) by 44.3% in the second quarter, according to the company in its most recent Form 13F...

Kennondale Capital Management LLC trimmed its holdings in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX - Free Report) by 62.5% in the second quarter, according to its most recent disclosure with the...

Savant Capital LLC bought a new position in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX - Free Report) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission...

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced at...